CCME Global Limited (BSE: 514336) is a Eluru, Andhra Pradesh-based company in the Biotechnology and Life Sciences industry. With a market capitalisation of ₹131 Cr, it ranks #3,012 by market cap among the 6,189 Indian listed companies on FinBizNet. At ₹30.42 (as of 28 Oct 2026), the share price is 83.2% below its 52-week high of ₹181.30 and 15.2% above its 52-week low of ₹26.41. The share price is down 75.2% over one year and down 73.9% over three months.
| Current Price | ₹30.42 |
|---|---|
| Market Cap | ₹131 Cr |
| BSE Code | 514336 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences |
| P/E Ratio | -54.7 |
| Return on Assets | -1.65% |
| 52-Week Range | ₹26.41 – ₹181.30 |
| 1-Year Price Change | -75.2% |
| 3-Month Price Change | -73.9% |
| Beta (1Y) | -0.61 |
| Headquarters | Eluru, Andhra Pradesh |
| Website | www.genesisiil.com |
CCME Global Limited does not have significant operations. The company was previously engaged in the manufacture and marketing of pro-biotic products for aquaculture, agriculture, poultry, and animal husbandry markets in India. The company was formerly known as Genesis IBRC India Limited and changed its name to CCME Global Limited in March 2026. CCME Global Limited was incorporated in 1992 and is based in Eluru, India.
1. Agricultural Biotech-This segment engages in manufacturing and marketing of PVC Pipes, bends, and couplings in India. 2. NA-NA 3. NA-NA 4. NA-NA
1. Agricultural Biotech-100%
CCME Global Limited is trading at ₹30.42, with a market capitalisation of ₹131 Cr.
CCME Global Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences).
CCME Global Limited has a P/E of -54.7.
CCME Global Limited is listed on the BSE under the scrip code 514336.
CCME Global Limited's share price is down 75.2% over one year and down 73.9% over three months. Its 52-week range is ₹26.41 to ₹181.30.
Data as of 28 Oct 2026. Descriptive market data only — not investment advice.